Hisoar Pharmaceutical's wholly owned subsidiary Zhejiang Hisoar Chuannan Pharmaceutical recently received the renewed Veterinary Drug Production License and Veterinary Drug GMP Certificate from the Zhejiang Provincial Department of Agriculture and Rural Affairs. The production scope covers non-sterile active pharmaceutical ingredients, including florfenicol with two production lines and flunixin meglumine, with validity until May 17, 2027. The company stated that the acceptance and renewal of certificates for the newly built and expanded florfenicol API production line mark the line's entry into commercial operation. This will further expand florfenicol production capacity reserves, enable rapid response to market supply and demand changes, and continuously strengthen core competitiveness. The company also noted that drug production and sales are subject to industry policies, market conditions, and other factors, and there are uncertainties.
Zhejiang Hisoar Pharmaceutical Co LtdNew florfenicol production line enters commercial operation, expanding capacity and enabling rapid response to market demand.